JL18008 Project Approved for Clinical Trials

                     in Both China and the United States

On March 11th, JECHO (Tianjin) Biopharmaceutical Co., Ltd.'s subsidiary, JECHO(Shanghai) Institute Co., Ltd, obtained clinical approval from the National Medical Products Administration (NMPA) to conduct clinical trials of JL18008, a Fusion Protein injection. This is another swift approval for the JL18008 project, following its approval for clinical trials by the United States Food and Drug Administration (FDA) in February this year. The JL18008 injection is intended for the treatment of HIV-infected immunological non-responders. This news represents a significant milestone for us and our first innovative drug product to receive IND approvals for both China and the United States.

                                                                                    Source: Center for Drug Evaluation (CDE), NMPA, China

JL18008, a long-acting IL-7 fusion protein, targets immune cell imbalances in HIV patients, enhancing immunity, slowing disease progression, and reducing the need for frequent drug administration, thereby improving patient compliance. This milestone underscores Jecho's commitment to innovation and international clinical development efforts.

JECHO (Shanghai) Institute Co., Ltd. (Located in Shanghai, China), a product research and development center. It is focused on new product development, pilot-scale process development, analytical methodologies, and the establishment of product quality standards.